Pfizer and Valneva announced that their Lyme disease vaccine candidate PF-07307405 (LB6V) demonstrated over 70% efficacy in preventing Lyme disease in individuals aged five years and older in Phase 3 VALOR trial. The vaccine candidate was well-tolerated.

Pfizer and Valneva announced that their Lyme disease vaccine candidate PF-07307405 (LB6V) demonstrated over 70% efficacy in preventing Lyme disease in people aged five years and older during Phase 3 VALOR trial. The companies also announced Valneva's participation in the 26th World Vaccine Congress in Washington DC.

Pomerantz LLP is investigating potential securities fraud claims against Valneva SE and partner Pfizer following the failure of their Phase 3 Lyme disease vaccine candidate (LB6V) to meet its primary endpoint. The announcement triggered a sharp 37.11% decline in Valneva's ADR price on March 23, 2026.

Valneva and Pfizer's Phase 3 VALOR trial for their Lyme disease vaccine failed to meet its primary endpoint due to fewer cases being accrued than expected. However, secondary analyses showed clinically meaningful efficacy of 73-75%, and Pfizer plans to proceed with regulatory submissions. Valneva shares fell 35.27% on the news, trading significantly below key moving averages.

Valneva has voluntarily withdrawn its IXCHIQ chikungunya vaccine BLA (Biologics License Application) and IND (Investigational New Drug) in the United States. The company is continuing to review global product opportunities based on medical need and commercial attractiveness. This decision comes as Valneva and Instituto Butantan announced initiation of a pilot vaccination campaign in Brazil with the single-shot vaccine.

Valneva has voluntarily withdrawn its Biologics License Application (BLA) and Investigational New Drug (IND) for IXCHIQ chikungunya vaccine in the United States. Simultaneously, the company is advancing a pilot vaccination campaign with Instituto Butantan in Brazil, continuing to evaluate the global product opportunity based on medical need and commercial attractiveness.

Valneva is consolidating its French operations at its Lyon site and finalizing R&D consolidation in Vienna. The company also reported positive Phase 2 results for its Lyme Disease vaccine candidate, showing sustained antibody levels and no safety concerns.

Valneva reported changes in its share capital and voting rights, including the issuance of new ordinary shares through stock option exercises and transfers of shares between November 6-28, 2025.

Valneva reported positive results from a Phase 1 trial of its second-generation Zika vaccine candidate, demonstrating an improved immune response compared to previous iterations.

Valneva reported changes in its share capital and voting rights, with a total of 171,958,275 ordinary shares and 187,722,356 net voting rights after transfers and free share attributions.

Valneva reported a change in its share composition, with 171,854,856 ordinary shares and a transfer of 653 shares with double voting rights between September 1-18, 2025.

Valneva reported its shares and voting rights status as of September 30, 2025, with 171,854,856 ordinary actions and 187,978,646 total voting rights, noting minor changes in share ownership and voting rights.